In a pharmacokinetic (PK) and pharmacodynamic (PD) trial in healthy participants, Samsung Bioepis' SB12 eculizumab biosimilar candidate demonstrated equivalence to Soliris, the reference product.
A phase 1 study of the proposed eculizumab biosimilar (SB12) vs reference product (Soliris) has demonstrated pharmacokinetic (PK) bioequivalence and comparable pharmacodynamic (PD), safety, and immunogenicity characteristics in a population of healthy volunteers, investigators reported at the 2021 American Society of Hematology meeting.
Eculizumab is a humanized monoclonal antibody that binds to human C5 complement protein and blocks hemolysis, or the breakdown of red blood cells. Eculizumab is currently indicated for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, refractory generalized myasthenia gravis, and neuromyelitis optica spectrum disorder.
Investigators sought to demonstrate comparable PK and PD in healthy individuals aged 18 to 55 years (N = 240) who were randomized in a 3-arm trial to a single 300-mg dose of SB12 or US- and EU-sourced reference product. Blood samples for analysis were collected over 64 days.
The primary end point was PK similarity between the various agents as determined by total drug exposure, or area under the concentration-time curve. Biosimilarity for the primary end point was confirmed, as the 90% CIs were within the predetermined equivalence margin of 80% to 125%, authors of the study wrote.
Investigators said there were no deaths or discontinuation of investigational products (IPs) due to treatment-emergent adverse events (TEAEs); they said there were 2 serious adverse events: renal colic in the SB12 cohort and back pain in the US-eculizumab group. “Both events were considered not related to the IP,” investigators wrote.
They said 70.0%, 65.0%, and 71.3% of patients in the SB12 and EU- and US-sourced eculizumab cohorts, respectively, experienced TEAEs, which investigators said was similar.
The number of participants who developed postdose antidrug antibodies (ADA) to eculizumab was 2 (2.5%), 1 (1.3%), and 0 (0.0%), respectively, authors wrote. “There was no significant difference between treatment groups. None of the [participants] with post-dose ADA to eculizumab had a positive result for neutralizing antibodies.”
Reference
Lee HA, Jang H, Kim Y, et al. A randomized, double-blind, single-dose phase 1 comparative pharmacokinetic study comparing SB12 (eculizumab biosimilar) with reference eculizumab in healthy volunteers. Presented at: ASH 2021; December 11-14, 2021. Abstract 929.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.